share_log
Reuters ·  May 7 07:01
Verve Therapeutics Inc - Heart-2 Enrolling Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment